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Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules 
that can be used for selective drug delivery. In this review, we discuss how scFvs help improve the specificity and efficiency of 
drugs. Small interfering RNA (siRNA) delivery using scFv-drug fusion peptides, siRNA delivery using scFv-conjugated nanoparticles, 
targeted delivery using scFv-viral peptide-fusion proteins, use of scFv in fusion with cell-penetrating peptides for effective targeted 
drug delivery, scFv-mediated targeted delivery of inorganic nanoparticles, scFv-mediated increase of tumor killing activity of 
granulocytes, use of scFv for tumor imaging, site-directed conjugation of scFv molecules to drug carrier systems, use of scFv to 
relieve pain and use of scFv for increasing drug loading efficiency are among the topics that are discussed here.
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The major drawback correlated with 
this type of antibodies is their large 
size, which may negatively affect their 
potency. Constant domains of antibod-
ies are not directly involved in antigen 
recognition and binding. Therefore, 
single-chain antibodies (scFvs), which 
are devoid of constant domains, are 
still able to bind their specific antigens 
(8,9). Because of their small size, scFvs 
are expected to display a higher cell 
penetration rate than their full-length 
counterparts; therefore, they are more 
INTRODUCTION
Targeted drug delivery systems have 
several advantages over traditional sys-
tems, including more safe movement 
through the cell membrane, reduced 
side effects and a higher efficiency (1–3). 
Antibody molecules, which specifically 
react with particular antigens on the 
cell surface, can serve as appropriate 
targeting elements/carriers for targeted 
drug delivery. Full-length antibodies 
are extensively used as the targeting 
elements of drug delivery systems (4–7). 
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favorable for use as targeting elements 
in drug delivery systems (10). This re-
view includes the most updated studies 
regarding the use of scFvs as targeting 
elements of drug delivery systems 
and presents innovative strategies for 
 increasing the efficiency of drug delivery 
systems, including liposomal and nonli-
posomal drug carriers.
USE OF SCFV MOLECULES FOR SIRNA 
DELIVERY
Efficient Delivery of siRNA to Breast 
Cancer Cells Using (Arginine)9– 
Anti-HER2-scFv Fusion Peptide
Small interfering RNAs ( siRNAs), 
which interfere with expression of mRNA 
molecules, have gained enormous atten-
tion for cancer treatment (11,12). A major 
drawback correlated with nontargeted 
siRNA delivery systems is the lack of 
specificity for the target cells. Jiang and 
colleagues used an anti-HER2-scFv 
antibody to specifically deliver siRNA 
molecules to HER2- overexpressing breast 
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time, patients acquire resistance to such 
inhibitors for several reasons, including 
point mutations in the EGFR intracel-
lular tyrosine kinase domain which 
annuls the binding of TKI to EGFR, 
mutation and subsequent activation 
of Kirsten rat sarcoma viral oncogene 
(KRAS),  epithelial-to-mesenchymal 
transformation, gene amplification of 
 mesenchymal-to-epithelial transforma-
tion (MET) factor and so forth (17–20). 
To overcome TKI resistance in lung 
cancer, Lu and colleagues produced a 
single-chain format of nimotuzumab, an 
 anti-EGFR monoclonal antibody, and 
used it to specifically deliver siRNA 
molecules to EGFR-expressing cells to 
suppress MET, EGFR and KRAS gene 
expression (21). The scFv contained 
result, anti-HER2-scFv molecules cannot 
recognize them. Reduced tumor me-
tastasis and prolonged animal survival 
have been the results of anti-HER2-scFv- 
mediated delivery of anti CXCR4-siRNAs 
to BT-474 xenograft-bearing mice (1).
siRNA Delivery Using (Arginine)9-
Anti-EGFR-scFv Fusion Peptide to 
Overcome Drug Resistance in Lung 
Cancer Cells
Epidermal growth factor receptor 
(EGFR) overexpression occurs in many 
types of human cancers including lung 
cancer (14–16). Tyrosine kinase inhibi-
tors (TKIs), which inhibit the tyrosine 
kinase activity of the EGFR intracellular 
domain, can suppress cancer progres-
sion. However, after a variable period of 
cancer cells to suppress the expression of 
chemokine receptor 4 (CXCR4), a protein 
that plays a main role in cell survival and 
cancer metastasis. The anti-HER2-scFv 
contained nine arginine residues at its 
C-terminal end (Figure 1A) (1).  Arginine 
residues are widely used to deliver 
 nucleic acids into cells; they act as a cell 
penetration peptide that binds the cells 
and transduces the siRNA molecules 
across the plasma membrane (Figure 1B) 
(13). The anti-HER2-scFv significantly 
increased the delivery of the siRNA mol-
ecules to HER2-positive BT-474 breast 
cancer cells and tumor xenografts, while 
it was unable to deliver siRNA molecules 
to MDA-MB-231 cells and tumor xeno-
grafts. MDA-MB-231 cells do not express 
HER2 receptors on their surface, and as a 
Figure 1. Structure and action mechanism of scFv-arginine fusion peptide and scFv-based immunoliposome (IL). (A) Nine arginine res-
idues act as a cell-penetrating peptide, which help the fusion peptide enter the cell. (B) Fusion peptide binds to a specific receptor 
on the target cell by its scFv moiety and enters the cell by its C-terminal tail arginine resides. (C) Cysteine residue at the C-terminal 
end  allows the scFv to form a covalent bond with PEG–PLA nanoparticles to create IL. (D) IL binds to the target cell through its scFv, 
 becomes internalized into the cell and releases the encapsulated drugs.
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amino acids) and used it for siRNA  
delivery to HeLa cells to suppress human 
wings apart-like (hWAPL) gene expres-
sion (26). Expression of this gene has 
been discovered to increase in human 
papilloma virus–related cervical cancer. 
t-Protamine has the ability to bind DNA; 
therefore, scFv-protamine fusion  peptide 
is expected to retain DNA-binding activ-
ity. Using enzyme-linked immunosor-
bent assay (ELISA) and gel shift assay, 
Zhang and colleagues showed that the 
fusion peptide retained both EGFR and 
DNA-binding activities. Expression of 
hWAPL mRNA was strikingly reduced in 
HeLa cells upon fusion peptide–mediated 
intranucleus delivery of hWAPL siRNA. 
Cell proliferation rate was also signifi-
cantly reduced (26). These results indicate 
that the scFv-t-protamine fusion peptide 
effectively delivered the siRNA molecules 
to the nucleus of target cancer cells.
siRNA-Mediated Gene Silencing in 
Dendritic Cells Using scFv-Coated 
Lipid Nanoparticles
Dendritic cells (DCs) play a critical role 
in immune responses (27), and therefore 
manipulation of their gene expression 
profile will influence their immunomod-
ulatory capacities. Inhibition of immune 
responses can help treat autoimmune 
diseases. DEC205 is a receptor expressed 
by DCs. Katakowski and colleague took 
advantage of this receptor for siRNA 
delivery to DCs to suppress immune 
responses (28). They produced a sin-
gle-chain format of an anti-DEC205 
monoclonal antibody and conjugated 
it to the surface of siRNA-loaded lipid 
nanoparticles. The scFv contained at its 
C-terminal end a 10-residue His-tag, a 
short glycine-serine linker (G4S) and an 
additional cysteine residue, allowing 
the site-directed conjugation to lipid 
components of siRNA delivery system 
(Figure 2A, B). scFv molecules bind lip-
ids through maleimide groups. siRNA 
molecules had been designed to target 
CD40, CD80 and CD86 genes. To examine 
whether the resultant immunoliposomes 
(ILs) are specific to DEC205, Katakowski 
and colleagues treated DEC205-positive 
nine additional arginine residues (9R) at 
its C-terminal end that guaranteed the 
penetration of fusion peptide (scFv-9R), 
and therefore delivery of siRNAs, into 
EGFR-positive cells. Control scFvs, 
which were devoid of C-terminal 9R, 
were unable to deliver siRNA molecules. 
siRNA molecules were loaded on scFv 
molecules by  simply mixing, and not by 
covalent bonds. EGFR-negative cancer 
cells (H69 cells) did not internalize siR-
NA-loaded fusion peptide, indicating 
that scFv moiety played a pivotal role in 
specificity of drug delivery to EGFR- 
expressing cells. scFv-9R-mediated 
siRNA delivery to H1993, H1975 and 
A549 cancer cells decreased the expres-
sion of MET, EGFR and KRAS genes, 
respectively. These cell lines carry MET 
amplification, L858R/T790M EGFR 
mutation and KRAS mutation, respec-
tively. Delivered siRNA molecules were 
able to suppress the growth of these 
cell lines significantly and restored their 
sensitivity to gefitinib (a TKI). Capacity 
of scFv-9R for siRNA delivery has been 
further confirmed in an animal model in 
which EGFR-specific siRNA decreased 
the growth of H1975 xenografts in nude 
mice and prolonged the survival time (21).
Covalent Conjugation of 
Anti-HER2-scFv to PEG–PLA 
Nanoparticles for siRNA Delivery 
to Cancer Cells
Polyethylene glycol–poly(D,L-lactide) 
(PEG–PLA)-based nanoparticles have 
been extensively used to encapsulate 
and deliver siRNA molecules to cancer 
cells. Dou and colleagues used this 
type of nanoparticles for delivery of 
antipolo-like kinase 1 (Plk1, a kinase 
enzyme involved in cell division) 
siRNA to breast cancer cells (22). They 
 conjugated an  anti-HER2-scFv anti-
body to the surface of siRNA-loaded 
PEG–PLA  nanoparticles and evaluated 
the  anticancer activity of the resultant 
conjugate on breast cancer cells. The 
scFv contained an additional cysteine 
residue at its C- terminal end (outside of 
antigen-binding sites, after  6-amino-acid 
His-Tag,  Figure 1C) which allowed it to 
covalently bind to PEG–PLA nanopar-
ticles via a thiol-maleimide coupling 
 reaction (22). The thiol-maleimide reac-
tion is a process that is widely used to 
bioconjugate biomolecules, including 
proteins (23,24).  Site-directed conju-
gation  permits the scFv to conjugate 
with another  molecule without losing 
affinity. Loss of affinity in nondirected 
conjugation may be due to induction 
of conformational change or block-
age of antigen-binding sites (25). The 
 anti-HER2-scFv-coated PEG–PLA 
nanoparticles (scFv HER2– NPsiRNA) 
were able to selectively deliver an-
ti-Plk1 siRNA to BT474 cells (HER2- 
overexpressing breast cancer cells) but 
not to HER2-negative MDA-MB-231. 
Compared with nontargeted nanopar-
ticles, the scFv-loaded nanoparticles 
(scFvHER2–NPsiRNA) were more potent in 
silencing of Plk1 gene in BT474. Non-
targeted nanoparticles were able to 
suppress the growth of both BT474 and 
MDA-MB-231 cells, indicating that they 
enter the cell in an unspecific manner. 
In contrast, scFvHER2–NPsiRNA caused 
significant growth inhibition only in 
the BT474 cells, demonstrating that the 
scFv portion increases the specificity to 
target cells. Using fluorescence imaging, 
Dou and colleagues demonstrated that 
scFv molecules present on the surface of 
the nanoparticles (Figure 1C, D) signifi-
cantly increased the tumor penetration 
rate (BT474 tumor xenografts) (22). 
These results all indicate that scFv mol-
ecules offer specificity to target cells and 
further increase the efficacy of PEG–
PLA nanoparticles in drug delivery.
Targeted siRNA Delivery to Cancer 
Cells Using a Fusion Peptide 
Composed of Truncated Protamine 
and a Cetuximab-Derived scFv
Anti-EGFR scFv antibody has also been 
used for drug delivery to cervical cancer 
cells. Zhang and colleagues produced 
a fusion peptide composed of variable 
domains of cetuximab (joined together 
with a short flexible linker, GGSSR SSSSG 
GGGSG GGG) and a truncated form of 
protamine (t-protamine, containing 22 
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siRNA had been designed to inhibit the 
expression of the virus nucleoprotein 
mRNA. They employed a humanized 
anti-HA scFv on the surface of liposome- 
encapsulated siRNA molecules to form 
ILs that were able to specifically target 
H5N1-infected cells, which express high 
level of viral HA on their surface. The 
nucleotide sequence of the anti-H5N1 
nucleoprotein was 5′-GGAUC UUAUU 
UCUUC GGAGd TdT-3′ for the sense 
strand and 5′-CUCCG AAGAA AUAAG 
AUCCd TdT-3′ for the antisense strand. 
Using immunofluorescence assay, Khan-
tasup and colleagues demonstrated  
that ILs bound to HA-expressing cells  
(baculovirus-infected Sf9 cells) much more 
scFv-Mediated siRNA Delivery to 
Avian Influenza Virus–Infected Cells
siRNA molecules have been found to 
be useful in controlling several viruses, 
including hepatitis B virus, dengue 
virus, adenovirus, respiratory syndrome 
virus, etc. (29–32). scFv molecules can 
be engaged to increase the specificity 
and efficiency of siRNA delivery to 
 virus-infected cells. Infected cells usually 
express viral antigens on their surface 
that can serve as a target for antibody. 
Khantasup and colleagues exploited one 
of such antigens, hemagglutinin (HA), 
to specifically deliver siRNA molecules 
to highly pathogenic avian influenza 
virus (H5N1)-infected cells (33). The 
and DEC205-negative CHO cells with ILs 
carrying Dy547-labeled siRNA (28). ILs 
showed approximately four-fold greater 
binding to DEC205-positive cells compared 
with nontargeted liposomes. Intravenous 
 injection of fluorescently labeled ILs in B6 
mice confirmed the role of anti-DEC205 
scFv in specificity of the carrier; significant 
uptake of lipid nanoparticles was observed 
only in DEC205-positive DCs. The siR-
NA-loaded ILs significantly reduced the 
expression of CD40, CD80 and CD86 genes 
in DCs (28). These results all indicate that 
anti-DEC205 scFv serves as an efficient tar-
geting element on the surface of liposomes 
and plays a critical role in the specificity of 
drug carrier systems.
Figure 2. Schematic view of a siRNA-loaded immunoliposome (IL) and a short peptide–scFv fusion peptide. (A) scFv molecules bind to 
PEG particles on the surface of siRNA-loaded IL to form a targeted siRNA carrier. (B) Targeting ligand of the IL consists of a scFv mol-
ecule, a short linker, 10 histidine residues and a cysteine residue that involves in covalently binding to PEG particles. (C) Amino acid 
sequence of TKKTLRT forms a short peptide with cell penetration capacity. (D) This short peptide allows the fusion peptide to enter the 
target cells previously recognized by scFv moiety.
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receptor-mediated endocytosis. Inside the 
endosomes, drug molecules may become 
inactive due to the acidic  environment; 
therefore, they must escape from en-
dosome to cytoplasm before lysosomal 
degradation (39,40). Use of Sendai virus 
F-protein has been proposed to avoid 
endosomal degradation. For safe and 
effective delivery of doxorubicin to can-
cer cells, Kumar and colleagues used 
a virus-based carrier, a fusion peptide 
composed a scFv [anti-PAP (placental 
isozyme of alkaline phosphatase)-scFv] 
and a part of Sendai virus F-protein 
(transmembrane domain and a part of 
cytoplasmic domain) (2). F-protein of the 
virus plays an important role in mem-
brane fusion and delivery of viral genetic 
materials to the host cells (41). The fusion 
protein (immuno-virosome) was able to 
selectively recognize, and deliver doxo-
rubicin molecules to, PAP-expressing 
cells [PAP-transfected HeLa and SaOs(T) 
cell lines] but not to fibroblast activation 
protein (FAP)-negative cells [CHO and 
SaOs(UT) cells]. The immuno-virosomes 
were found to deliver doxorubicin mole-
cules to the cytoplasm of FAP-expressing 
cells chiefly through membrane fusion 
and not by endocytosis (2). Treatment 
of HeLa cells with cytochalasin B, which 
inhibits endocytosis, resulted in only a 
slight decrease in immuno-virosome in-
ternalization, indicating that endocytosis 
has not been the main way of internaliza-
tion. These results indicate that the car-
rier (immuno-virosome) recognizes the 
target cells by its scFv moiety and enters 
these cells by its viral section.
Increased Specificity, Internalization 
Rate and Cytotoxicity Using scFv 
Diabody-Mediated Drug Delivery
Single-chain antibodies are usually 
produced by linking VH and VL do-
mains of antibodies via a flexible peptide 
linker (composed of ~15 amino acids) 
that allows the assembly of domains 
to form paratopes, the antigen-binding 
sites (9). By shortening the linker be-
tween two adjacent VL and VH domains, 
they fail to assemble to form a regular 
scFv; however, they can assemble with 
of hydrogel- encapsulated scFv-loaded 
nanoparticles reduced the colon expres-
sion of CD98 and  diminished the severity 
of colitis (37). These results all indicate 
that scFv plays a pivotal role in the spec-
ificity of the siRNA delivery system and 
can serve as a suitable targeting ligand 
on the surface of drug carriers to target 
CD98-expressing cells.
USE OF SCFV FOR SMALL MOLECULE 
DELIVERY
Delivery of the Collagen-Binding 
Domain to Collagen-Enrich 
Carcinoma Using Anti-EGFR scFv
As a main constitute of extracellular 
matrix (ECM), collagen can potentially 
act as a barrier to drug absorption; 
therefore, it is considered an important 
target for cancer therapy. A short pep-
tide sequence (TKKTLRT), well known 
as collagen-binding peptide (CBP), has 
been proven to specifically target col-
lagen type 1 and significantly increase 
drug penetration. Liang and colleagues 
produced a fusion peptide composed 
of CBP and a cetuximab-based scFv 
antibody (expressed in Pichia  pastoris) 
(Figure 2C, D) and evaluated its activity 
on A-431 cells and xenografts (10). A-431 
is an EGFR-overexpressing skin cancer 
cell line. They found using immunocy-
tochemistry and flow cytometry analysis 
that the cetuximab-based scFv bound to 
EGFR with the same affinity as that of 
full-length cetuximab. The fusion peptide 
was able to induce apoptosis and inhibit 
cell proliferation in vitro. They also found 
that CBD–scFv fusion protein penetrated 
the tumors more rapidly than intact 
cetuximab and significantly reduced the 
tumor growth, demonstrating that scFvs 
are more amenable than their full-length 
counterparts for use as targeting ligands 
of drug carriers. Besides binding to colla-
gen, CBD has been proven to enhance the 
 retention time of scFv in tumors (10).
Safe and Targeted Drug Delivery 
Using scFv-Viral Peptide Fusion Protein
Antibody-drug conjugates can be in-
ternalized from the cell surface through 
efficiently than nontargeted liposomes (33). 
They also compared the antiviral activity 
of both ILs and nontargeted liposomes on 
H5N1-infected Madine-Darby canine kid-
ney cells to discover how much the scFv 
improves the siRNA delivery system. ILs 
were found to be more potent than non-
targeted liposomes in reducing viral titer. 
These results indicate that the scFv plays 
a pivotal role in internalization of siRNA 
into virus-infected cells (33).
TARGETED SIRNA DELIVERY TO 
MACROPHAGES AND COLONIC 
CELLS TO REDUCE COLITIS
CD98 is a cell surface receptor found 
to be overexpressed in colonic tissues of 
mice with colitis, on the surface of intesti-
nal T cells (CD4+ T cells and CD8+ T cells) 
and B cells of patients with inflamma-
tory bowel disease (IBD) and in intestinal 
macrophages (34–36). As CD98 plays an 
important role in progression of IBD, it can 
serve as a potential target for therapy of 
IBD patients. Xiao and colleagues took ad-
vantage of this cell surface antigen to spe-
cifically target colonic epithelial cells and 
macrophages to reduce colitis (37). They 
applied an  anti-CD98 scFv on the surface 
of  anti-CD98  siRNA-loaded nanoparticles. 
The nanoparticles were composed of PEG, 
urocanic acid and  low-molecular-weight 
(2 kDa) polyethylenimine (PEI) (37). 
It has been demonstrated that the mo-
lecular weight of PEI plays an important 
role in terms of cytotoxicity; the lower 
the molecular weight, the higher the 
cell viability and transfection  efficiency 
(38). 3-(4,5-dimethylthiazol-2-yl)-2, 
5- diphenyltetrazolium bromide (MTT) 
assay revealed that  scFv-loaded nanopar-
ticles did not alter the viability of Colon-26 
cells and RAW 264.7 macrophages, while 
PEI/siRNA complex induced significant 
cytoxicity. The  scFv-loaded nanoparticles 
were able to enter Colon-26 cells, RAW 
264.7  macrophages, bone marrow– derived 
macrophages and colitis tissues and ex-
hibited excellent lysosomal escape ability. 
In Colon-26 cells and RAW 264.7 mac-
rophages, the scFv-loaded nanoparticles 
reduced the level of CD98 significantly. In 
the mice with colitis, oral administration 
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ranpirnase-diabody, and evaluated their 
cytotoxicity for various EGFR-expressing 
cells. They found that enzymatic activity 
of ranpirnase-scFv was a little lower 
than that of ranpirnase alone. The enzy-
matic activity of ranpirnase-diabody was 
very  considerable, nearly twice the activity 
an anti-EGFR antibody in delivering 
ranpirnase to EGFR- expressing cells 
and tumors (ranpirnase is an RNase 
inhibitor-resistant ribonuclease capable 
of degrading tRNA molecules) (42). They 
produced a scFv, a diabody and two 
fusion proteins, ranpirnase-scFv and 
other  VH-linker-VL domains on the 
same strands to form an active scFv. 
The  resultant  construct, called diabody, 
has antigen-binding sites twice that of a 
monovalent scFv (Figure 3A). Kiesgen 
and colleagues compared the capac-
ities of scFv and diabody formats of 
Figure 3. Structure and/or functional mechanism of some scFv-based drug carriers. (A) Monovalent and bivalent formats of Ranpirnase–
scFv fusion peptide. Ranpirnase and scFv are joined together with a linker peptide. (B) Schematic view of a doxorubicin-loaded bi- 
specific IL. The targeting ligand is a fusion peptide composed two scFv molecules, anti-FAP scFv and anti-CD105 scFv. (C) Deferoxamine 
(DFO)-loaded anti-FAP IL. Anti-FAP scFvs contain a cysteine residue in their linker region that makes a covalent bond with PEG molecules 
on the surface of liposomes. The resultant ILs are able to bind FAP proteins expressed on the surface of TGF β1-activated fibroblasts and 
reduce collagen deposition. (D) Adriamycin (ADM)-loaded scFv molecule. Dextran can serve as a linker for effectively loading ADM 
molecules on scFv molecules. (E) A nanodisk composed of reconstituted high-density lipoprotein particles and apo-AI–anti-CD20 scFv 
fusion peptide to specifically deliver curcumin to CD20-positive non-Hodgkins lymphoma (NHL) cells. The fusion peptide constitutes the 
protein scaffold of nanodisk and binds NHL cells through its scFv moiety. The structure of nanodisk has been derived from the work of 
Crosby and colleagues (71).
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indicate that diabodies may be superior 
to single-chain antibodies for use as tar-
geting ligands of drug carriers.
Targeted Delivery Using A Disease-
Specific Cell Surface Receptor 
and scFv
Cell- or tissue-specific antigens 
 provide an opportunity to specifically 
deliver anticancer drugs to that cell or 
tissue, without affecting normal cells. 
One such antigen is the fetal acetylcho-
line receptor (fAChR) that is expressed 
in rhabdomyosarcoma (RMS), the most 
common soft-tissue sarcoma in chil-
dren. Brehm and colleagues took ad-
vantage of this receptor for delivery of 
 microtubule-associated protein (MAP) 
to RMS (49). They produced a fusion 
peptide composed of a fully humanized 
anti-fAChR scFv antibody (called scFv35) 
and MAP and evaluated its  specificity 
and cytotoxicity for fAChR-positive cell 
lines (FL-OH1 and RD). The scFv35–
MAP fusion peptide selectively recog-
nized the fAChR-positive cell lines while 
it was unable to bind  fAChR-negative 
cell line U937 (human histiocytic 
lymphoma cell line). Compared with 
the positive control fusion peptide 
(scFv35-Pseudomonas exotoxin A, 
scFv35-ETA), the scFv35-MAP displayed 
an increased internalization rate, but a 
decreased cytotoxicity, in  fAChR-positive 
cell lines. Cytotoxicity assay using an-
other fusion peptide (scFv35-SNAP, a 
negative control peptide) revealed that 
cytotoxicity was due to effector proteins 
(MAP and ETA) and not scFv35 moiety 
(49). Although scFv35-MAP was proven 
to be relatively less toxic than scFv35-
ETA, MAP-based drugs still maintain 
great interest since they are potentially 
less immunogenic than those of foreign 
origin (such as bacterial exotoxins).
Dual-Targeting Carrier for Delivery of 
Doctexal to Ovarian Cancer Cells
Huang and colleagues designed a 
dual targeting carrier and evaluated its 
capacity in delivering the anticancer 
drug doctexal (TXT) to ovarian cancer 
cells (50). The carrier was composed of 
Enhanced Delivery of Doxorubicin 
Using Liposomes Armed With a 
Bispecific scFv
Diabodies, which are composed of 
two different scFv blocks, can simulta-
neously target two different antigens on 
the cell surface. To determine whether 
such diabodies can improve drug de-
livery efficiency, Rabenhold and col-
leagues produced two scFv molecules 
(one targeting CD105 and the other 
targeting FAP) and one single-chain 
bispecific diabody (scDb, containing 
the two scFvs together; Figure 3B) and 
evaluated their capacity in delivering 
liposome-encapsulated doxorubicin 
to the target cells (48). They modified 
scFv molecules to contain a sulfhy-
dryl group offering the potency to 
couple with another scFv. ILs derived 
from the scFv and diabody molecules 
were examined on different cell lines, 
including the cell line expressing 
CD105 (HUVEC cells) and a fragment 
antigen-binding (Fab)-transfected fibro-
sarcoma cell line (called HT1080-Fab) 
expressing both CD105 and FAP. The 
liposomes with anti-FAP alone, which 
they called scFv′FAP-IL, were unable 
to bind HUVEC cells, while those 
carrying anti-CD105 scFv [including 
monospecific anti-CD105 scFv ILs (called 
scFv′CD105-IL), bispecific ILs (combi-
nation of the two ILs, called scFv′FAP/
CD105-IL) and bispecific single-chain 
diabodies (called scDb′​CD105/FAP-IL)] 
were capable of binding these cells. To 
the T1080-Fab cells, the maximum inter-
action belonged to scDbCD105/FAP-IL 
and then to scFv′FAP/CD105-IL. In 
contrast, the minimum interaction 
belonged to scFv′CD105-IL and then 
to scFv′FAP-IL. Compared with un-
armed liposomes (control liposomes), 
the CD105-carrying ILs all were able 
to induce considerable cytotoxicity in 
HUVEC cells (up to 59% reduction in 
cell viability), whereas scFv′FAP-IL 
could not affect cell viability signifi-
cantly. For HT1080-Fab cells, scD-
bCD105/FAP-IL has been relatively 
more toxic than other ILs but less toxic 
than free doxorubicin (48). These results 
of ranpirnase-scFv. Both ranpirnase- 
diabody and ranpirnase-scFv entered 
the cell more rapidly than cetuximab. 
 Ranpirnase induced a significant cy-
totoxicity in both EGFR-positive and 
 EGFR-negative cells, indicating that it 
enters the cell in an EGFR-independent 
manner. The capacity of ranpirnase for 
cytotoxicity induction was not much 
less than that of ranpirnase-scFv, but 
it was strikingly lower than that of 
 ranpirnase-diabody (42). The results 
all indicate that diabodies can serve 
as suitable carriers for targeted drug 
delivery.
Using scFv to Increase Tumor-Killing 
Activity of Granulocytes. TNF-related 
apoptosis-inducing ligand (TRAIL) is a 
cytokine protein involved in apoptosis 
induction in tumor cells (43,44). Stud-
ies have indicated that the truncated 
form of TRAIL (sTRAIL) produced by 
enzymatic cleavage of its extracellular 
domain still retains proapoptotic activity 
and can be employed to increase antitu-
mor capacity of T cells and leukocytes 
(45,46). Phagocytes express a surface  
antigen, called C-type lectin-like  
molecule-1 (CLL1), which can be ex-
ploited for targeted drug delivery to 
these cells. Wiersma and colleagues 
produced a fusion peptide composed of 
an anti-CLL1-scFv and sTRAIL to spe-
cifically deliver TRAIL to granulocytes 
(47). They found that the fusion peptide, 
called CLL1:TRAIL, was able to specifi-
cally bind to and increase the antitumor 
activity of granulocytes. CLL1:TRAIL 
binds to granulocytes through its scFv 
moiety and triggers apoptosis through 
TRAIL. To examine whether CLL1:TRAIL 
synergizes the anticancer effect of mono-
clonal antibodies, they co-treated FaDu 
(EGFR-expressing cells) and Ramos 
B cells (CD20-expressing cells) with 
CLL1:TRAIL-armed granulocytes and a 
relevant monoclonal antibody (cetuximab 
and rituximab, respectively). In both 
cases, apoptosis was increased signifi-
cantly, indicating a potential role of  
antibody-dependent cell-mediated cy-
totoxicity in synergizing the anticancer 
activity of CLL1:TRAIL (47).
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in the stromal fibroblasts of epithelial 
cancers. Fibroblasts of normal adult tis-
sues express undetectable levels of FAP 
(55). To generate an in vitro model of 
fibrosis, Schuster and colleagues isolated 
primary normal human lung fibroblasts 
from adult lung tissue and treated them 
with transforming growth factor β1 
(TGF β1; to induce fibrosis-stimulating 
conditions), and ascorbate and proline 
(for collagen synthesis) (53). Unlike 
 deferoxamine-loaded nontargeted lipo-
somes, which were not able to decrease 
collagen deposition, deferoxamine-loaded 
ILs significantly reduced collagen depo-
sition (Figure 3C). Free deferoxamine 
did not reduce collagen deposition (53). 
These results indicate that anti-FAP 
scFv plays a significant role in  
delivering deferoxamine molecules to 
fibroblasts.
USE OF SCFV MOLECULES FOR 
DELIVERY OF INORGANIC 
NANOPARTICLES
scFv-Mediated Targeted Delivery of 
As2O3-Nanoparticles to Liver Cells to 
Inhibit Tumor Angiogenesis
Vascular endothelial growth factor 
(VEGF) plays an important role in tumor 
angiogenesis in different human cancers 
(56); therefore, it is regarded as suit-
able target for cancer therapy. Among 
chemical therapeutics, arsenic (As2O3) is 
widely used for cancer therapy owing 
to its potent anticancer activity (57–59); 
however, it lacks specificity to cancer 
cells and induces toxicity in normal cells. 
To specifically deliver As2O3 nanoparti-
cles to liver cancer cells, Xiangbao and 
colleagues produced a humanized  
anti-VEGFR-2 scFv antibody (via ribo-
some display technique) and evaluated 
its ability to deliver arsenic to liver 
cancer xenografts (60). Humanized anti-
bodies have lower immunogenicity than 
nonhuman antibodies (9) and reasonably 
are preferred for use as a drug carrier 
in the human body. As2O3-loaded scFv 
(anti-VEGFR-2-scFv-As2O3) significantly 
increased the concentration of As2O3 
in tumor tissues of nude mice and 
to recognize FAP-negative cell lines. In 
contrast, the control liposomes (contain-
ing cysteine instead of anti-FAP scFv) 
weakly interacted with HT1080-mFAP 
cells; they were able to enter neither 
HT1080-mFAP nor HT1080 cells (wild-
type cells). These results indicate that 
the uptake of anti-FAP-ILs depends on 
the interaction of FAP (on the cancer 
cell surface) and anti-FAP scFv (on the 
liposomes). In vivo analysis of tumor xe-
nografts of HT1080-mFAP and HT1080 
cells have shown that anti-FAP-ILs can 
specifically bind to and image FAP- 
expressing tumors. Control liposomes, 
on the other hand, have been shown 
to accumulate in stromal phagocytes, 
which can be exploited for drug/dye 
delivery to these cells (25).
Use of Anti-FAP scFv for Specifically 
Delivering Deferoxamine to FAP-
Expressing Cells to Reduce Collagen 
Deposition
Excessive deposition of ECM com-
ponents results in fibrosis. One of the 
major components of ECM is collagen, 
whose deposition has been well docu-
mented in development of fibrosis (51). 
Iron is necessary as a coenzyme for ac-
tivity of prolyl-4-hydroxylase (P4H), an 
enzyme involved in collagen synthesis 
(52). Deferoxamine is an iron chelator 
that can inactivate P4H and reduce 
collagen deposition; however, its poor 
absorption and short half-life limits its 
therapeutic efficacy. To overcome these 
problems, Schuster and colleagues en-
capsulated deferoxamine molecules in 
PEG-functionalized ILs (scFv-conjugated 
liposomes) that were able to specifically 
target FAP-expressing cells. The scFv 
contained an additional cysteine residue 
within its linker region that allowed 
site-directed conjugation to liposomes 
(53). A cysteine residue within linker 
region serves as a suitable site for conju-
gation (Figure 3C). The influence of cys-
teine residue position on the success of 
conjugation process and activity of resul-
tant ILs has been previously studied by 
Messerschmidt and colleagues (54). FAP 
is a serine protease selectively expressed 
three main parts: a central core made 
from iron oxide (Fe3O4) nanoparticles—
offering magnetism-targeting function, 
β-cyclodextrin (β-CD) units—providing 
holes for encapsulation of TXT and an 
antiendoglin scFv antibody for selec-
tively targeting of ovarian cancer cells. 
Endoglin is a cell membrane protein 
that can be used to target ovarian cancer 
cells. Magnetic targeting assay displayed 
that the carrier could be directed by 
an external magnetic field. ELISA with 
 endoglin-expressing ovarian cancer cells 
Scov3 indicated that the scFv antibody of 
the carrier (containing TXT) retained its 
binding capacity to endoglin. Anticancer 
activity of the carrier has been found to 
be due to the TXT molecules encapsu-
lated in β-CD since the TXT-less carriers 
did not affect the viability of Scov3 cells. 
TXT-loaded carriers were more cytotoxic 
than raw TXT and exhibited a sustained 
release of TXT (until 94 h). TXT-loaded 
carrier has not been toxic for HUVECs 
(50). These results demonstrate that the 
dual-targeting carrier is an efficient drug 
carrier system to specifically deliver TXT 
to ovarian cancer cells.
Selective Fluorescence Imaging of 
FAP-Expressing Tumors Using an scFv-
Based IL
Exploiting a tumor-specific antigen 
can help selectively target cancer cells in 
tumor tissues. One such type of antigens 
is FAP α, a transmembrane protein with 
enzymatic activity that is expressed by 
tumor-associated fibroblasts. Ruger and 
colleagues took advantage of this pro-
tein to selectively and efficiently detect 
cancer cells. They used a type of lipo-
some (containing DY-676-COOH dye) 
capable of emitting fluorescence only 
upon cellular uptake and degradation. 
For selective delivery to FAP-expressing 
cells, they used an anti-FAP scFv anti-
body as targeting ligand. The antibody 
was first conjugated to MalPEG2000-
DSPE micelles and then inserted into 
the liposomes to form anti-FAP ILs. The 
resultant ILs could selectively recognize 
FAP-transfected human fibrosarcoma 
cells (HT1080-mFAP cells) but they failed 
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an anti-EGFR scFv on the surface of 
IONPs to examine whether it could in-
duce immune responses (66). To produce 
scFv-conjugated INOPs, they coated the 
surface of IONPs with an amphiphilic co-
polymer layer containing active  carboxyl 
groups, which served as conjugation 
sites for amine PEG carboxyl to generate 
PEG-modified IONPs with surface car-
boxyl groups. These carboxyl groups, in 
turn, served as conjugation sites for scFv 
molecules to produce scFv- conjugated 
INOPs (66). Intravenous injection of 
near-infrared (NIR)-830 dye- labeled-scFv-
conjugated IONPs to Balb/c mice bear-
ing 4T1 mouse mammary tumors led 
to accumulation of the nanoparticles in 
tumor tissues. Repeated injection (two 
times, 200 pmol each) of scFv-conjugated 
IONPs resulted in high-level secretion of 
anti-scFv-specific antibody. No antibody 
secretion was detected in the serum sam-
ples of the mice injected with nontargeted 
nanoparticles. Interestingly, when Yang 
and colleagues encapsulated doxorubicin 
molecules in the scFv-conjugated IONPs 
and applied them on the mice, they 
found a significant decrease in murine 
anti-scFv-specific antibody secretion (66). 
These results indicate that the antibody 
response against scFv is not an issue for 
development of scFv-conjugated doxo-
rubicin-loaded nanoparticles for cancer 
therapy (66).
USE OF SCFV AND DEXTRAN TO 
INCREASE DRUG LOADING EFFICIENCY
The number of loaded drug molecules 
per drug carrier unit can be an index of 
efficiency of that system for drug deliv-
ery. Chen and colleagues used a glucan 
compound, dextranT10, as a linker to 
load adriamycin (ADM) molecules on 
hepatocellular carcinoma-specific scFv 
molecules (scFv-SA3; Figure 3D) (67). 
They found that each scFv in the conju-
gate (ADM-Dextran–scFv-SA3) bound 
to ~14 ADM molecules. The conjugate 
significantly reduced the proliferation 
and colony formation of HepG2 cells 
in vitro and decreased the growth of 
tumor xenografts in nude mice. The con-
jugate was unable to bind the negative 
USE OF SCFV TO INHIBIT THE RELEASE 
OF PAIN-RELATED PEPTIDE IN SENSORY 
NEURONS
Botulinum toxin type A (BTX-A) has 
gained enormous attention as a pain 
reliever since it can cleave synaptoso-
mal-associated protein 25 (SNAP-25) 
and therefore prevents pain-related 
peptides from being released (63). No-
ciceptive sensory neurons express high 
levels of a surface receptor, called P2x 
purinoceptor (P2x3), which can be en-
gaged to specifically target these cells. 
Ma and colleagues exploited this recep-
tor for selectively delivering BTX-A to 
nociceptive sensory neurons (64). They 
designed and produced a fusion peptide 
composed of an anti-P2x3 scFv (called 
MH7C) and a part of BTX-A (including 
protease light chain, translocation and 
N-terminal half moiety of the binding 
domain) and evaluated its specificity for, 
and SNAP-25 cleaving activity in, dorsal 
root ganglion (DGR) neurons. The fusion 
peptide (called LC-HN-HCN/A-MH7C) 
specifically recognized DGR neurons 
and significantly increased the cleavage 
of SNAP-25. The LC-HN-HCN/A-MH7C-
mediated cleavage occurred at strikingly 
lower concentration when compared 
with the control protein (LC-HN-HCN/A). 
The fusion peptide exhibited a high 
degree of safety for mice in such a way 
that it did not cause any mortality or 
behavioral disorders in mice (~25 g) even 
at high concentration (200 μg), whereas 
BTX-A caused mortality at significantly 
lower concentration (20 pg) (64). These 
results indicate that scFv-mediated drug 
delivery to sensory neurons not only 
decreases the drug dosage necessary for 
pain relief but also reduces the toxin- 
related mortality.
TARGETING LIGANDS OF 
DOXORUBICIN-LOADED IONPS DOES 
NOT CAUSE A IMMUNE RESPONSE
A potential drawback associated with 
the use of targeting ligands on the sur-
face of drug carrier system is to induce 
ligand-specific antibody responses, which 
may disturb the cellular uptake of the 
carriers (65). Yang and colleagues  applied 
prolonged survival time. Survival time 
in mice treated with As2O3-loaded scFv 
was longer than that in mice treated 
with As2O3 nanoparticles or scFv alone 
(60). Anti-VEGFR-2 scFv-As2O3 has 
been found to significantly suppress the 
proliferation, invasion and migration 
of human hepatoma cancer cell line 
Bel 7402. The antitumor capacity of an-
ti-VEGFR-2 scFv-As2O3 has been proven 
in vivo as well, where it was able to in-
hibit the growth of Bel 7402 tumor xeno-
grafts in BALB/c nude mice (61).
USE OF SCFV FOR DELIVERY OF IRON 
OXIDE NANOPARTICLES FOR TUMOR 
IMAGING
Selective delivery of imaging agents 
to tumor tissue makes it possible to 
selectively image that tumor. Kanazaki 
and colleagues produced a trastuzum-
ab-based scFv and used it to selectively 
deliver iron oxide nanoparticles (IONPs) 
of different sizes (20, 50 and 100 nm) to 
HER2-expressing cells and tumor xeno-
grafts (62). IONPs have a biodegradable 
nature and represent low cytotoxicity, 
making them a favorable probe for pho-
toacoustic cancer imaging. Among the 
scFv-conjugated IONPs (they named 
the resultant conjugations, based on the 
size of their IONPs, SNP20, SNP50 and 
SNP100), SNP20 displayed the highest 
binding affinity to, and the highest accu-
mulation rate in tumor xenograft of, N87 
cells (HER2-expressing human gastric 
cancer cells). In N87 tumor-bearing mice, 
SNP20 injection notably increased pho-
toacoustic signal, but failed to increase 
the signal in mice bearing the xenograft 
of SUIT2 cells, pancreatic cancer cells 
expressing low levels of HER2. Fur-
thermore, 20-nm IONPs alone (without 
scFv) increased photoacoustic signal in 
neither N87 nor SUIT2 tumors. Berlin 
Blue staining of N87 and SUIT2 tumors 
treated with SNP20 has revealed that 
N87 tumors uptake relatively greater 
amounts of IONPs (62). These results all 
indicate that scFv offers a high degree 
of specificity toward HER2-expressing 
cells/ tumors and can serve as an efficient 
carrier of IONPs for imaging purposes.
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Table 1. Summary of a number of studies concerning the use of single-chain antibodies in drug delivery systems.
Type of carrier/drug delivery 
system Targeting ligand Evaluated in vitro/in vivo Result(s) Ref.
Temozolomide (TMZ)-loaded 
IL (scL-TMZ)
anti-transferrin receptor 
scFv
U87, U251, U87R (a TMZ-resistant 
subclone of U87)
Mice bearing glioblastoma 
multiforme tumors
Enhanced killing activity against 
U87 and U251 cells (compared 
with noncapsulated TMZ), 
sensitization of U87R to TMZ.
Prolonged animal survival time
(72)
Fusion peptide
composed of scFv format of 
PiPP mAb and pseudomonas 
exotoxin (PE38)
human chorionic 
gonadotropin (hCG)-
specific scFv
hCG-expressing cells 
(U937, MOLT4 and A549 cells)
killing of hCG-expressing cancer 
cells without affecting 
PBMCs
(73)
Fusion peptide composed of 
viral interleukin-10 (vIL-10), 
MMP cleavable linker and 
anti-ROS-CII scFv
An scFv-targeting ROS-
modified collagen 
type II (anti-ROS-CII 
scFv)
mouse MC-9 mast cells + arthritic 
C57BL/6 mice
Increased cell proliferation +
Specific localization in arthritic 
knee + reduced inflammation
(74)
Mixing of doxorubicin–loaded 
mPEG-NPs and BsAbs 
(noncovalent binding)
humanized 15-2b anti-
mPEG Fab fragment 
+ human anti-EGFR 
scFv/anti-HER2-scFv
SW480 (EGFR+ cells) and SK-BR-3 
(HER2+ cells
BALB/c nude mice bearing 
xenograft of SW480/SW620 cells
Preferential binding to EGFR+/
HER2+ cancer cells
Significantly increased 
suppression of tumor growth 
when compared with 
nontargeted nanoparticles
(75)
Azido-functionalized protein 
nanocapsules loaded with 
GFP
Anti-HER2-scFv SKBR3 (HER-2-overexpressing cell 
line) and MDA-MB-231 (triple-
negative cell line)
Specific delivery of GFP to SKBR3 
cells + no florescence in MDA-
MB-231 cells
(76)
scFv-CD40L fusion peptide 
(EpCAM:CD40L)
Anti-EpCAM scFv EpCAM-transfectant cell line HEK293.
EpCAM
Induction of paracrine CD40 
signaling in tumor-resident 
immature dendritic cells (iDC), 
maturation of DCs + activation 
of T cells.
(77)
scFv-CD40L fusion peptide 
(-CD20:CD40L)
Anti-CD20 scFv CD20+ leukemic B cells 
(BJAB and Raji)
Induction of CD40 signaling, 
induction of cell death
Fusion peptide composed of 
Bluetongue virus VP2 protein 
and APCH
APCH (an scFv 
recognizing  
antigen-presenting 
cells)
guinea pigs, 
IFNAR–/– mice, 
and cattle
Enhanced humoral and cellular 
immune response in IFNAR–/– 
mice (when compared with VP2 
alone + high titer of specific NAs 
in pigs and cattle
(78)
Fusion peptide composed 
of an anti-EGFR VHH and 
iRGD (a tumor-penetrating 
peptide, CRGDK GPDC)
VHH (variable domain 
of heavy chain of 
 anti-EGFR antibody)
2D culture,  
multicellular spheroids (3D) culture, 
and tumor xenograft of BGC-823 cells 
(Human gastric adenocarcinoma 
cell line)
Enhanced antitumor activity 
when compared with anti-EGFR 
antibody alone + penetration 
into deeper zone of multicellular 
spheroids and tumors + …
(79)
crosslinked albumin 
nanoparticles targeting 
HGFR (c-Met)
Anti-HGFR nanobody 
(Anti-c-Met nanobody)
TOV-112D (Met-negative cells),  
TOV + Met (Met-transfected TOV-
112D cells), MKN45, A549, A431
Specific binding to Met-expressing 
cells + internalization and lysosomal 
degradation of Met-targeted 
nanoparticles (evaluated in 
MKN45 and A549 cells)
(80)
Fusion peptide composed 
of scFv and nuclear 
localization signal (NLS)
scFv-targeting nuclear 
export signal (NES, 
C-terminus of
mutated NPMc+)
NPMc + -transfected HeLa cells and 
OCI-AML3 (human acute myeloid 
leukemia cells)
Accumulation of fusion peptide in 
the nucleus + effective binding to 
NPMc+ in the cytoplasm + failing 
to relocate NPMc+ in the nucleus
(81)
Rous sarcoma virus-like 
particles Displaying scFv 
antibody
scFv format of 
humanized CC49 
antibody (anti-TAG-72 
antibody)
LS174T human colon 
adenocarcinoma 
Cells (TAG-72-expressing cells) + 
HEK293 cells (control cells)
Selectively killing of LS174T cells 
by FITC/DOX-loaded carrier
(82)
Continued on next page
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of the studies included in this review 
indicate that scFv molecules have a high 
potential for use as targeting ligands, 
either on the surface of encapsulated 
drugs or in fusion with therapeutic 
proteins. scFv molecules can be conju-
gated to carriers by either covalent or 
noncovalent bonds. Cysteine residues 
within linker region or after His-tag 
(outside of scFv molecule) can serve as 
a suitable site for site-directed conjuga-
tion, allowing the scFv to make a strong 
linkage with carriers without losing its 
affinity. The results presented in this 
review indicate that scFv molecules are 
efficient targeting ligands for use in 
drug delivery systems. Some scFv-con-
jugated drug delivery systems discussed 
in this review have been studied only 
in vitro, while others have been further 
evaluated in animal models (tumor xe-
nografts). Many drugs are efficacious 
in in vitro conditions, but few of them 
display efficacy in tumor xenografts 
(animal model) and fewer in clinical 
trials; therefore, the scFv- conjugated 
drug delivery systems presented in this 
review need to be further evaluated in 
animal model and/or clinical trials to be 
approved for therapeutic applications.
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 indicate that the scFv moiety is respon-
sible for specificity of the fusion peptide 
for CD20-positive cells, guaranteeing a 
targeted drug delivery to these cells.
In addition to the carriers described 
above, a number of fusion peptides and 
other types of carriers (including lipo-
some-based and non–liposome-based 
carriers) have been designed and evalu-
ated for targeted drug delivery; however, 
because of space limitations, we do not 
describe them in detail. A summary of 
these studies is presented in Table 1.
CONCLUSION
scFvs can serve as targeting ligands 
on the surface of encapsulated drugs 
or in infusion with a protein drug for 
specific drug delivery. They can also 
be used for effectively loading a drug 
into the cells of interest, as we saw 
in the case of adriamycin delivery to 
hepatocellular carcinoma cells. Mono-
specific scFv diabodies can increase the 
specificity, internalization rate and cyto-
toxicity of drugs, offering an enhanced 
possibility to treat cancer. Bispecific 
scFv diabodies, which simultaneously 
bind to two different antigens on a cell 
surface, can help increase the efficiency 
of drug liposome-based delivery sys-
tems and therefore improve the therapy 
of diseases. scFv molecules in fusion 
with cell-penetrating peptides (e.g., 
truncated protamine and arginine-rich 
peptides) or some viral peptide (e.g., 
transmembrane domain of F- protein 
of Sendai virus) are potentially able to 
enhance the cell penetration rate and 
hence the accumulation of drug within 
the  target cells. Collectively, the results 
control (QSG-7701 cells), indicating the 
role of scFv molecules in specific binding 
to HepG2 cells. The conjugate was more 
potent than either ADM alone or ADM/
scFv-SA3 combination (67). Collectively, 
the results indicate that dextranT10 can 
be used as an efficient linker for drug 
loading on scFv molecules.
ADDITION OF SCFV TO PROTEIN 
SCAFFOLD OF LIPOPROTEINS TO OFFER 
SPECIFICITY TOWARD TARGET CELLS
Reconstituted high-density lipopro-
teins (rHDLs) have been widely used 
to deliver small drug molecules to cells. 
rHDL have a protein scaffold usually 
consisting of apolipoproteins (sum-
marily called apo) (68–70). The major 
drawback correlated with rHDL-medi-
ated drug delivery is the lack of spec-
ificity for the cells to which the drug 
is going to be delivered. Crosby and 
colleagues used an engineered protein 
scaffold to overcome the lack of speci-
ficity associated with  rHDL-mediated 
drug delivery (Figure 3E) (71). They 
designed a fusion peptide composed of 
an anti-CD20 scFv and human apo A-I 
and evaluated its capacity for curcumin 
delivery to either CD20-positive or 
 CD20-negative cells. They found that 
curcumin accumulated only in the 
 CD20-positive cell lines (non-Hodgkin’s 
lymphoma cells: Ramos and Granta 
cell lines). Fluorescence- activated cell 
sorting analysis revealed that the fu-
sion peptide bound to CD20-positive 
cell lines through its  anti-CD20 scFv 
section. The fusion peptide was unable 
to bind the CD20- negative cell line (Jur-
kat)  substantially (71). These results all 
Table 1. Continued.
scFv-TR1 fusion protein scFv-specific for 
mesothelin, a tumor 
marker
wild-type Jurkat cells 
+ J-Meso (Jurkat cells engineered to 
express human mesothelin) 
+ OVCAR3 
(ovarian cancer cell line-expressing 
mesothelin)
Selectively killing of mesothelin-
positive cells
(83)
APCH, antigen presenting cell homing; BsAbs, bispecific antibodies; DOX, doxorubicin; FITC, fluorescein isothiocyanate; GFP, green fluorescent 
protein; H5N1, Highly Pathogenic Avian Influenza A; HGFR, hepatocyte growth factor receptor; MMP, matrix-metalloproteinase; mAb, 
monoclonal antibody; mPEG-NPs, methoxy PEGylated nanoparticles; NAs, neutralizing antibodies; PBMCs, peripheral blood mononucleated 
cells; ROS, reactive oxygen species; TAG-72, tumor-associated glycoprotein-72; 2D culture, two-dimensional monolayer culture.
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